PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. - Wikidata - wikimedia - TriplyDB

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

http://www.wikidata.org/entity/Q36359469

about

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.PD-L1 Status in Refractory Lymphomas.Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells Future perspectives for personalized immunotherapy in renal cell carcinoma.Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile and transcriptional landscape.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components.High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by 18F-FDG PET/CT: a Case Report and Review of Literature.Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis.

P2860

Q30276874-C71695F1-F7B2-46ED-A0F0-C0BC87ADF029 Q36197517-7B729E62-0630-4F3A-A8A2-E7ACA04441A1 Q36646352-1509965A-5C3C-41E8-9687-211C22AC6191 Q37303319-AE6BFB59-1787-42CE-93B8-CC659875EFDA Q38673583-79E934CF-5CB4-456B-9AD7-1E1ECC0B5C88 Q38678106-F21ECBD2-A865-4D96-90FA-536BD03E9C67 Q38910154-26B6456B-1FCB-4321-94BA-D32147C462F8 Q39395931-73457E35-56CB-481B-B39A-4308738BB74E Q40498385-D6912156-A3F7-442E-A650-7EF09D4B32AA Q46670559-A95459EC-FAA5-4EC6-BC04-6DAD594BF4FB Q47188564-DF3C9356-CECA-4B2F-B47B-A5AAAFD621C9 Q48036216-450FEEB8-619B-4306-893E-157B36769156 Q48168816-4D95F838-BF4D-4C00-9BBA-E35E2112E56E Q49186124-3C6795BF-1381-4BA5-A469-55F7756B2EDF Q52657082-7129B90C-3200-4851-B86F-683CE7ABE008 Q52735485-2AC1815B-4FBF-48D3-ACC4-C17FCDDD08B5 Q55263000-5871832A-C5FE-439F-A0D8-076D2C026F78 Q55440617-DF60802B-6AEE-44F6-B188-2835711F6539

P2860

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

http://www.wikidata.org/entity/Q36359469

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@ast

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@en

type

label

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@ast

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@en

prefLabel

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@ast

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@en

P1433

Q36359469-45717A78-40F5-498E-9215-BB62EAC34677

P1476

Q36359469-8C909B2F-4381-4053-9A86-CB3913BE7A63

P2093

Q36359469-29C9F2B1-8A59-4F45-B986-B51342283681

Q36359469-5C01FC90-AA86-46AB-8406-B87C323E946E

Q36359469-68B6EEB5-2072-4A0C-B8B4-575F591ED54D

Q36359469-86781824-38E9-42E5-86FD-B790017D4232

Q36359469-8A3559AC-724E-4758-9CE3-522EDE4A6C8A

Q36359469-A61A7E0B-CA80-4808-B7C9-AF1ECB21A41F

Q36359469-D985E828-13F5-4EAF-BC97-49E010B7CE63

Q36359469-E92E45D5-0526-4385-A0D9-BE2A34AEB84D

P2860

Q36359469-061A7FA8-A4B6-4D16-AA37-E2AA77C310D6

Q36359469-0D2CF48D-2FB5-4DEF-9797-7DCCBC4FCB6D

Q36359469-148989A8-9B8C-40DF-A9EA-56B13A789DC7

Q36359469-429C84FC-2930-4C9F-8EB9-DAF5E0CF55EA

Q36359469-49D0E544-A1EA-4F73-94F6-E45C0AA90706

Q36359469-5F9207AB-570F-4DBD-BC90-9CB672E56D62

Q36359469-650B07D3-03D2-4BD1-9D00-DA7A4569A184

Q36359469-6B8FF314-B5E3-421F-8385-603D6D05E8E7

Q36359469-743F413D-8D78-4107-BDFA-9E7CF28F0DBD

Q36359469-8991B5EC-5E08-4765-9632-A3763492F08B

P304

Q36359469-8FD77149-C168-4E21-BD9B-4BD2DFD32B5C

P31

Q36359469-9312C46B-E6E2-4D79-8CFF-EB3D0B2677FE

P356

Q36359469-DE3BA852-1681-4D6F-BBAB-A033686AF442

P433

Q36359469-4806586D-9C34-4671-A2DD-303532116AF4

P478

Q36359469-C4E98203-E2C1-4A63-AD9F-FA1474EF8703

P50

Q36359469-2F67A69B-BC3D-4F7C-B4D5-7FE60D9A17F3

Q36359469-422FFCAA-3FFF-4EAA-97A5-B0563414AE81

Q36359469-7E12C289-4448-4FA9-8309-91AEEA1BFF59

P577

Q36359469-7F5980F1-E61A-46A1-BE8F-F0F032D37FB7

P698

Q36359469-BDC8354D-0259-465A-878C-C3C090D00FB1

P932

Q36359469-E693204E-9A0F-4F12-9FA1-FF7E53B63C72

P356

2326-6066.CIR-15-0150

P1433

Cancer immunology research

P1476

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

@en

P2093

David Bryant

http://www.w3.org/2001/XMLSchema#string

Erik P Castle

http://www.w3.org/2001/XMLSchema#string

Estrella M Carballido

http://www.w3.org/2001/XMLSchema#string

Melissa L Stanton

http://www.w3.org/2001/XMLSchema#string

Nicholas J Vogelzang

http://www.w3.org/2001/XMLSchema#string

Sandeep Reddy

http://www.w3.org/2001/XMLSchema#string

Sherri Z Millis

http://www.w3.org/2001/XMLSchema#string

Zoran Gatalica

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Tissue microarrays: one size does not fit all

Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature.

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

PD-L1 expression in nonclear-cell renal cell carcinoma.

P304

1303-1307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-15-0150

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Richard W. Joseph

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26307625

http://www.w3.org/2001/XMLSchema#string

P932

4674298

http://www.w3.org/2001/XMLSchema#string